Immunotherapy combo shows promise against tough colorectal cancer
NCT ID NCT07160647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery to 29 patients with a specific genetic type of colorectal cancer (MSI-H/dMMR). The goal is to see if this combination can completely eliminate the tumor before surgery. Researchers will also study tissue samples to better understand who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and Tuvonralimab (immunotherapy drugs targeting PD-1 and CTLA-4 proteins)
- What this could lead to
- If successful, this could offer a more effective pre-surgery treatment option for certain colorectal cancers, potentially increasing the chance of complete tumor removal.
- What could go wrong
- This is a small, early-phase study (29 participants) with no control group. The drugs may cause immune-related side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMMR/MSI-H-TYPE RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang, 310016, China